Testing neuroEPO for mild to moderate Alzheimer's disease
Part of Brain & nervous system clinical trials.
This trial tests a nasal spray form of neuroEPO, a protein that may protect brain cells, in people with mild to moderate Alzheimer's. You must have a caregiver who can help with study visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have mild to moderate Alzheimer's (a doctor's rating of 3–5 on the Global Deterioration Scale and a CDR score of 1–2)
- Your Mini-Mental State Exam score is between 14 and 26
- You have a caregiver who is willing to take part
- You are not taking blood thinners (like warfarin, heparin, or NOACs) and have no bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This study tests an experimental oral medication (EI-1071) to see if it can reduce brain inflammation in people with Alzheimer's disease. The goal is to learn if it is safe and might help slow cognitive decline.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This Phase 1 trial tests how safe and tolerable ALN-APP is in people with early Alzheimer’s-related mild memory impairment or mild dementia. It may help researchers find a treatment path for early Alzheimer’s, while closely monitoring side effects and basic health markers.
This trial tests whether a pulsed electromagnetic field (a non-drug device that uses magnetic pulses) can help people with mild to moderate Alzheimer’s. Participants typically stay on stable Alzheimer’s medicines and follow daily home treatments during the study.
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
Hear when a new Mild Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.